News
The latest in GLP-1 medications, obesity research, and weight loss science — editorially curated daily.
AI-generated illustrationObesity Drug Trial Participants Abandon Studies After Identifying Placebo Treatment
Patients in obesity drug trials frequently recognize placebo treatments and withdraw from studies to seek effective GLP-1 medications, creating challenges for clinical trial validity.
AI-generated illustrationGLP-1 Medications Drive Gym Members from Cardio to Weight Training
Fitness trainers report gym members using GLP-1 medications are shifting from cardio equipment to strength training as appetite suppression reduces their reliance on high-calorie burning workouts.
AI-generated illustrationGLP-1 Drugs Cut Death Risk 28% in Diabetic Cancer Patients with Brain Metastases
Retrospective study of 711 patients shows 28% lower three-year mortality in diabetic cancer patients with brain metastases who used GLP-1 drugs versus other diabetes medications.
AI-generated illustrationFDA Approves Novo Nordisk's Awiqli as First Weekly Insulin for Type 2 Diabetes
The FDA approved Novo Nordisk's Awiqli as the first once-weekly insulin for type 2 diabetes, reducing injections from 365 per year to 52 while maintaining glucose control comparable to daily options.
AI-generated illustrationFood Companies Market 'GLP-1 Friendly' Labels Without FDA Standards
Companies are marketing foods as 'GLP-1 friendly' without FDA standards defining the term, targeting the growing population taking weight-loss drugs.
AI-generated illustrationGLP-1 Medications Reduce Depression Risk by 20% Independent of Weight Loss
New research analyzing 240,000 patient records shows GLP-1 medications reduce depression risk by 20% through direct brain effects, independent of weight loss benefits.
AI-generated illustrationGLP-1 Users Show 15% Lower Atrial Fibrillation Recurrence After Ablation
A 500-patient observational study found GLP-1 users had 22% atrial fibrillation recurrence after catheter ablation compared to 37% with other weight loss methods over 18 months.
AI-generated illustrationFDA Warns Novo Nordisk Over Unreported Deaths and Strokes in GLP-1 Users
The FDA warned Novo Nordisk for failing to properly report deaths and strokes among GLP-1 users, citing systematic failures in safety reporting for Ozempic and Wegovy.
AI-generated illustrationEli Lilly Business Development Head Reveals Strategic Focus on Late-Stage Metabolic Assets
Eli Lilly's business development chief revealed the company's strategy for acquiring late-stage metabolic disease assets to expand beyond GLP-1 medications, while Merck's $2.7 billion Terns acquisition targets liver disease treatments.